Scienture Holdings (SCNX) Price to Sales (2025 - 2026)
Scienture Holdings' (SCNX) quarterly Price to Sales came in at 41.82 in Q2 2026, down 79.66% quarter-over-quarter from 205.59 in Q1 2026.
Analysis
Scienture Holdings (SCNX) Price to Sales (2025 - 2026) Analysis & Trends
Scienture Holdings has disclosed Price to Sales across 2 years of filings, most recently posting 41.82 for Q2 2026.
- In Q2 2026, Price to Sales changed N/A year-over-year to 41.82; the TTM figure through Jun 2026 stood at 35.04 (up 1045.42% YoY), while the FY2025 annual figure was 18.13, down 87.87% from the prior year.
- Price to Sales came in at 41.82 for Q2 2026 at Scienture Holdings, down from 205.59 in the prior quarter.
- In the past five years, Price to Sales ranged from a high of 1323.17 in Q1 2025 to a low of 41.82 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn |
| 10 | Scienture Holdings | 15.19 Mn | 15.19 Mn | 335,779.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 41.82 |
| Mar 31, 2026 | 205.59 |
| Mar 31, 2025 | 1,323.17 |